EP0879044A1 - Vernis a ongles antifongique et methode associee - Google Patents

Vernis a ongles antifongique et methode associee

Info

Publication number
EP0879044A1
EP0879044A1 EP96903559A EP96903559A EP0879044A1 EP 0879044 A1 EP0879044 A1 EP 0879044A1 EP 96903559 A EP96903559 A EP 96903559A EP 96903559 A EP96903559 A EP 96903559A EP 0879044 A1 EP0879044 A1 EP 0879044A1
Authority
EP
European Patent Office
Prior art keywords
griseofulvin
nail lacquer
lacquer composition
nail
weight percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96903559A
Other languages
German (de)
English (en)
Other versions
EP0879044A4 (fr
Inventor
Marcel E. Nimni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transdermal Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US1996/000710 external-priority patent/WO1997025962A1/fr
Publication of EP0879044A1 publication Critical patent/EP0879044A1/fr
Publication of EP0879044A4 publication Critical patent/EP0879044A4/fr
Withdrawn legal-status Critical Current

Links

Definitions

  • the present invention is directed to a nail lacquer containing an anti-fungal effective amount of griseofulvin.
  • nail lacquer compositions contain film-forming compounds and organic solvents. Depending on the organic solvent, the griseofulvin may be soluble or somewhat soluble at ambient temperatures in such solvent. Thus, the griseofulvin may be in solution in the nail lacquer, partially in solution and partially suspended in the nail lacquer, or be totally suspended in the nail lacquer. When the griseofulvin is partially or totally suspended in the nail lacquer, the nail lacquer should also contain a suspending agent such as bentonite.
  • a suspending agent such as bentonite.
  • the fingernails and toenails are susceptible to dermatophytic infections which are caused by the invasion of fungi into the nails of human beings and other animals.
  • fungi such as T. rubrum, Microsporum Canis, T. mentagrophytum, T. interdigitale, and other known fungi that can cause these types of infections.
  • the treatment of these infections typically involves administering one or more known types of antifungal agents, e.g., griseofulvin, clotrimazole, miconazole nitrate and thiabendazole, either orally or topically depending on the particular anti-fungal agent used.
  • griseofulvin may be administered when the dermatophytic infection has not been successfully treated with the topical application of other antifungal agents.
  • infections of the nails The general rule is that, if not treated very early, these infections progress to become chronic and are essentially not responsive to any form of therapy, except on some occasions, to prolonged administration of orally administered griseofulvin and a few other new antifungal agents.
  • griseofulvin due to their insolubility and associated poor adsorption from the gastrointestinal tract, have to be administered in relatively large doses, for long periods of time, sometimes extending for more than one year, and have a series of undesirable side effects.
  • orally administered griseofulvin there is concern that the oral use of griseofulvin includes a risk of toxicity. It is generally believed that this risk may be reduced if griseofulvin could be successfully topically administered.
  • the topical administration of griseofulvin has been hindered by the lack of a suitable carrier, since griseofulvin cannot be topically applied and absorbed through the dermis in its natural solid or powder state.
  • griseofulvin is insoluble in water and only slightly soluble in common solvents, such as dimethylsulfoxide, dimethylformamide and acetone which are typically used as pharmaceutical carriers.
  • common solvents such as dimethylsulfoxide, dimethylformamide and acetone which are typically used as pharmaceutical carriers.
  • the following articles which discuss the topical application of griseofulvin using various carrier systems are aimed at the skin surface rather than the nails.
  • Topical griseofulvin therapy of that which is called tinea pedis by Goldman, et al., ASMC Dermato Venerologica, line 39, page 454-460 (1959);
  • the activity of various topical griseofulvin preparations and the appearance of oral griseofulvin in the stratum corneum by Knight, British Journal of Dermatology, Vol.
  • the highly volatile solvents e.g. acetone
  • the oily solvents or ointment carriers even when demonstrated as potentially effective as carriers, typically were applied in relatively excessive amounts leaving an oily residue even after the lapse of an extended period of time.
  • Topical griseofulvin compositions are also disclosed in U.S. Patent No. 3,899,578, issued to Bird, et al., August 12, 1975.
  • the disclosed compositions are comprised of griseofulvin dissolved in various high boiling, volatile solvents, e.g. propylene carbonate, di ethylphthalate, 3 phenoxypropanol, 4-chlorophenoxyethanol, phenoxyethanol, phenylethanol, eugenol and benzyl alcohol.
  • Benzyl alcohol in combination with dimethyl phthalate, propylene carbonate or eugenol are disclosed as preferred solvent carriers.
  • the composition may be diluted with ethanol, n-propanol, isopropanol, propylene glycol or glycerol.
  • the disclosed compositions would be generally classified as a gel, ointment or paste due to the large amount of the low volatile solvent used in their preparation.
  • these compositions will leave an oily residue for a considerable amount of time after application. It is believed that griseofulvin is solubilized in the oily layer of the composition and will rub off on the clothing or upon washing and thus will not be absorbed to any great extent by the skin.
  • U.S. Patent No. 4,820,724 also discloses a griseofulvin composition for topical application to the skin.
  • the solvent carrier system disclosed in this patent is a mixture of a fugitive solvent having a boiling point of less than 110°C and a delivery solvent having a boiling point of greater than 120°C.
  • the delivery systems described in this patent are effective in promoting the absorption of griseofulvin through the skin; however, the delivery systems are easy to remove accidentally and therefore are not convenient to use.
  • compositions for application to or treatment of nails including nail polishes, nail polish removers, nail oil emulsions, and the like have been developed.
  • U.S. Patent No. 3,382,151 describes an aqueous- based, formaldehyde-containing composition which can be applied to fingernails to strengthen them against cracking and splitting. The patent further discloses that the product possesses aseptic properties, curing some inflammation of the matrix of the nail and killing fungi which occasionally infect nails.
  • U.S. Patent No. 4,250,164 describes a nail polish composition, which has added thereto an anti-psoriasis effective amount of a topical steroid effective against psoriasis.
  • 2,799,613 describes the use of dibromo- pentachlorocyclohexane as a topical fungicide and bactericide and also discloses including it as an ingredient of nail polish.
  • Certain oil-containing compositions have been disclosed as being useful as nail and cuticle conditioners or softeners.
  • U.S. Patent No. 2,765,257 indicates that sulfonated mineral oil acts as an effective cuticle softener; while sulfonated animal and vegetable oils are not effective.
  • Other prior art e.g., U.S. Patent No. 4,286,609, has disclosed the soaking of fingertips in a hot, aqueous emulsion of vegetable and animal oils to moisturize, smooth and soften the surface of the nails and the tissue surrounding the nails.
  • U.S. Patent No. 4,810,498 refers to nail oil composition consisting of a cosmetic oil containing jojoba oil and tolnaftate. This substance is prescribed to treat fungal infections in nails, particular sculptured nails, known for their propensity to become contaminated. This type of formulation, although potentially effective if applied frequently has the difficulty that it has an oily texture which will only display its properties while present on the nail, and is easily removed by rubbing or when hands are washed with detergents.
  • U.S. Patent No. 4,957,730 described a nail varnish comprising a water insoluble film forming substance and a series of antimycotic compounds derived from a l-hydroxy-2- pyridone structure.
  • the present invention provides a method and composition for application of griseofulvin to the nail surface, which will adhere tenaciously and yet continue to deliver the active anti ⁇ fungal compound (griseofulvin) into and through the nail.
  • the present invention is predicated upon the surprising discovery that when griseofulvin is added to a nail lacquer and the nail lacquer is applied to the toenails and/or fingernails, the griseofulvin is effective in preventing and/or alleviating dermatophytic infections of the nails to which the anti-fungal nail lacquer is applied.
  • the nail lacquer of the present invention includes, at a minimum, an organic film former which is in solution in a solvent system of one or more biocompatible organic solvents which, upon application to the nails, evaporate, leaving a relatively hard water permeable film.
  • organic film former which is in solution in a solvent system of one or more biocompatible organic solvents which, upon application to the nails, evaporate, leaving a relatively hard water permeable film.
  • film-forming compounds and solvent systems therefor are well known in the art and no detailed exemplification thereof is deemed necessary.
  • the film-forming compounds are those which form a film which is relatively hard and strong, such film- forming compounds including polymers and copolymers of vinyl acetate, polymers and copolymers of acrylic or methacrylic acid (e.g., polymethyl methacrylate) polyvinylacytel and polyvinylbutyrals.
  • a particular preferred film-forming compound is nitrocellulose, either alone or in combination with one or more of the other film- forming compounds mentioned above.
  • Physiologically acceptable solvent systems which will dissolve the film-forming compounds mentioned above, are known in the art and include either alone or in combination lower alkyl alcohols such as ethyl, butyl and isopropyl alcohols, aromatic solvents such as benzyl alcohol, and butyl, ethyl, and amyl acetate.
  • the solvent system preferably contains a combination of organic solvents, at least one of the organic solvents having a boiling point of below about 100°C (e.g. between 40°C or 50°C and 100°C) and at least one organic solvent having a boiling point above 100°C (e.g. 110°C - 200°C) .
  • nail lacquer compositions also include a plasticizer to render the film more elastic.
  • Plasticizers are also generally known in the cosmetic art and includes camphor, dibutyldioctyl and diphenyl phthalate and tricresyl and triphenyl phosphate.
  • ingredients of the nail lacquer include, if desired, colorants and pigments such as titanium oxide, mica, bismuth oxychloride, etc. If insoluble colorants and pigments are used, then a suspending agent such as bentonite should also be in the nail lacquer composition in order to prevent settling out of such insoluble colorants and pigments.
  • the amount of solvent in the nail lacquer composition of the present invention should, of course, be sufficient to solubilize and dissolve the film-forming compounds. Generally speaking, the amount of film-forming compound, relative to the organic solvent system, is relatively small. For example, the weight rate of film former to organic solvent will range from 1:3 to 1:10.
  • the film- forming solution i.e. the film former and organic solvent system
  • the amount thereof will be relatively minor compared to the amount of film former.
  • the weight ratio of fil - forming compound to plasticizer will be between about 5:1 to 20:1.
  • a suspending agent should also be present in the nail composition if an insoluble colorant or pigment is used and, in addition, if griseofulvin is present in an amount greater than that which is dissolved in the organic solvents of the nail lacquer composition.
  • the amount of suspending agent is not critical and will generally be present in amounts of from 1 to 10 weight percent.
  • the amount of griseofulvin in the nail lacquer compositions of the present invention is generally between about 0.5 weight percent and 10 weight percent with a preferred amount being between about 2 weight percent and 8 weight percent with a most preferred amount being between about 2 weight percent and 5 weight percent.
  • the griseofulvin is present in an amount of between about 1.5 or 2 weight percent and 3 weight percent, the remaining portion of the griseofulvin is undissolved and suspended in the nail lacquer composition.
  • a suspending agent such as an organic clay (e.g., bentonite) is added, which allows the griseofulvin to remain in the nail lacquer composition as a colloidal suspension.
  • a portion of the griseofulvin be in solution and a portion of the griseofulvin be in suspension.
  • a portion of the griseofulvin be in solution and a portion of the griseofulvin be in suspension.
  • the griseofulvin leaches out of the nail lacquer to exert its' fungistatic effects.
  • Small filter paper discs impregnated with the lacquer and allowed to dry, when placed on culture dishes containing T.
  • the invention is directed to a composition which is comprised of at least 0.1 weight percent griseofulvin in a clear lacquer which is essentially similar in composition to that used to manicure nails.
  • This composition can be topically applied to the infected sites (nails and surrounding tissue) which exhibits signs of fungal infection.
  • the invention is further directed to methods of making and using the composition, considering that the drug remains in solution and/or suspension for prolonged periods of time.
  • the griseofulvin containing lacquer Once the griseofulvin containing lacquer is applied to the nail it rapidly hardens and forms a water permeable film containing the griseofulvin following the evaporation of the solvent system. This not only concentrates the griseofulvin at or near the site where it is needed, but it is believed facilitates the transport of the active compound through the patient's nail. Thus not only does the nail lacquer composition of this invention provide a means for applying a concentrated amount of an active compound but also promotes transport of the compound through the nail. It should be noted that the above discussion concerning the mechanism of absorption is merely a theory based on observed facts and should not be taken in any manner to limit the scope of the invention.
  • the nail lacquer composition may be prepared by admixing the solvents, film former and active compound in a suitable manner which assures the solubilization and/or suspension of the griseofulvin in the solvents.
  • composition may be applied to the affected area by any suitable means.
  • this composition of the invention may be used to treat various types of dermatophytic infections.
  • this composition may be used to treat the various dermatophytid infections, and nail infections caused by fungi (Onychomycosis) .
  • These types of infections may be caused by numerous fungi, e.g., those classified under the genera: trichophyton, microsporum or epidermophyton.
  • the antifungal agent griseofulvin used to treat fungal infections in accordance with this embodiment of the invention is represented by the following general formula: Compound Parts by Weight
  • the resulting composition is topically applied directly to the infected site. After application the solvents quickly dissipate by evaporation, due to the body temperature of the patient, leaving as a residue a thin water soluble film on the affected area.
  • the composition may be applied to the affected area by any satisfactory means, such as a small brush, cotton swab or spatula, being the most satisfactory.
  • the effective amount of the composition applied to the infected area is such to provide a thin layer of the residue after evaporation of the solvents.
  • the precise amount of the composition is not critical, however, excessive application will not be beneficial.
  • Removal of the lacquer should be accomplished periodically by using a suitable solvent (usually every 2-4 days) . This could be achieved with any nail polish remover available commercially, or preferably a mixture of acetone-plant or animal tissue oil (9:1) containing 1% griseofulvin in solution. This maintains the levels of drug in the tissue and the oil prevents the nails from becoming brittle, a problem which is particularly prevalent in individuals suffering from such infections.
  • this composition ensures that the griseofulvin remains in the lacquer for a sufficient enough time on the patient's nail to allow for absorption of the griseofulvin. Furthermore, the topical application of griseofulvin using this composition allows a several order of magnitude reduction in the amount of griseofulvin given the patient in comparison with oral administration. This reduces the potential risks associated with the oral administration of griseofulvin as discussed above and the potential of skin irritation caused by the solvent.

Landscapes

  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composition de vernis à ongles antifongique contenant un agent filmogène, un solvant pour ledit agent et une quantité antifongique de griséofulvine qui peut être soit en suspension, soit en solution dans ladite composition. Pour utiliser la composition de vernis à ongles antifongique, on l'applique sur l'ongle d'un doigt ou d'un orteil et on la laisse en contact avec l'ongle jusqu'à ce que les solvants s'évaporent et qu'une couche mince de griséofulvine reste sur l'ongle.
EP96903559A 1996-01-18 1996-01-18 Vernis a ongles antifongique et methode associee Withdrawn EP0879044A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1996/000710 WO1997025962A1 (fr) 1994-03-17 1996-01-18 Vernis a ongles antifongique et methode associee
CA002243566A CA2243566A1 (fr) 1994-03-17 1996-01-18 Laque antifongique pour ongles et methode connexe

Publications (2)

Publication Number Publication Date
EP0879044A1 true EP0879044A1 (fr) 1998-11-25
EP0879044A4 EP0879044A4 (fr) 1999-03-31

Family

ID=25680381

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96903559A Withdrawn EP0879044A4 (fr) 1996-01-18 1996-01-18 Vernis a ongles antifongique et methode associee

Country Status (1)

Country Link
EP (1) EP0879044A4 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989008442A1 (fr) * 1988-03-11 1989-09-21 Seton Products Limited Preparations topiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989008442A1 (fr) * 1988-03-11 1989-09-21 Seton Products Limited Preparations topiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9725962A1 *

Also Published As

Publication number Publication date
AU707437B2 (en) 1999-07-08
EP0879044A4 (fr) 1999-03-31
AU4760796A (en) 1997-08-11

Similar Documents

Publication Publication Date Title
US5487776A (en) Anti-fungal nail lacquer and method therefor
US5993790A (en) Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections
CA1157380A (fr) Preparations renferment du methylsulfonylmethane, et methodes d'utilisation et de purification
JP2868768B2 (ja) 二相溶媒組成物の調製方法
RU2261701C2 (ru) Противоинфекционные комбинации активных веществ и их применение для местного лечения грибковых заболеваний ногтей пальцев стоп и кистей
TW213414B (fr)
JP4004182B2 (ja) 乳化組成物
JP4133837B2 (ja) 皮膚保湿用ゲルおよび方法
DK1888024T4 (en) Topical compositions
JPH0564924B2 (fr)
EP0954278A1 (fr) Compositions pharmaceutiques contenant de l'huile de noix de kukui
JP4359140B2 (ja) 異常な角質性物質を除去するための製剤
JP3653098B2 (ja) 爪真菌症治療用のグリセリルトリアセテートの使用
EP1408750A2 (fr) Composition dermatologique en creme / poudre
US20080112908A1 (en) Anti-fungal nail lacquer
JPH0597627A (ja) 角栓除去剤
AU707437C (en) Anti-fugal nail lacquer and method therefor
AU707437B2 (en) Anti-fugal nail lacquer and method therefor
JP2007505051A (ja) 活性物質として置換２−アミノチアゾールを含む抗真菌マニキュア剤
JP2001513747A (ja) 抗真菌性の爪ラッカーおよびその製法
JP6989150B2 (ja) Ｈｐｖ皮膚感染症の治療のための医療デバイス
KR20220001161A (ko) 천연물 유래 추출물을 포함하는 피부 보호용 조성물
JP2003055138A (ja) プロポリス含有シート状化粧料
CA2713125A1 (fr) Compositions d'acide acetique/thymol et leur utilisation dans le traitement de l'onychomycose
FR3053333A1 (fr) Melange liquide contenant du 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one et un com-pose de niacinamide, et composition cosmetique le contenant

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980818

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IE IT LI LU NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TRANSDERMAL THERAPEUTICS INC.

A4 Supplementary search report drawn up and despatched

Effective date: 19990211

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19991227

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000708